The Gambia Government, through the Ministry of Health and Social Welfare and MRC Unit The Gambia, have worked collaboratively to determine the impact of the introduction of pneumococcal conjugate vaccines (PCV) on severe pneumococcal pneumonia, sepsis and meningitis.
The report from the European and African Clinical Research Bibliometric analysis of publications within the scope of The European & Developing Countries Clinical Trials Partnership (EDCTP) 2003 – 2011, highlights MRC Unit The Gambia’s contribution towards reducing the global burden of diseases.
Dr Grant Mackenzie, Principal Investigator of the Pneumococcal Surveillance Project, has secured an 18 month funding extension to continue with surveillance of pneumococcal infections at MRC Basse Field Station worth £1 million.
In a ceremony attended by senior representatives of the Gambian Government, MRC Unit The Gambia handed over equipment to the Ministry of Health and Social Welfare through the Global Fund Asset Transfer, on Tuesday 23rd December 2014.
New findings published in The Lancet reveal the changing burden of disease over more than 20 years on a global scale, including a fall in the number of deaths caused by pneumonia and measles in The Gambia.
Introduction of the meningococcal A conjugate vaccine 10 short years after development is a public health success story and is already showing promise of significant impact. With the Meningitis Vaccine Project coming to a close in December 2014, we celebrate MRC Unit The Gambia’s role in the project, working in partnership with the Gambian Government […]
There is no need to spray insecticide on walls for malaria control when people sleep under treated bed nets, according to new research published in The Lancet.
In a truly South-South collaboration, scientists from MRC Unit The Gambia and the University of Dakar, UCAD Senegal, are conducting a joint trial to determine the safety and interference of the malaria vectored vaccines when given together with EPI vaccines to young Gambian infants, funded through the Malaria Vectored Vaccine Consortium 2 (MVVC2).
The wide-reaching impact of research conducted at MRC Unit The Gambia has been recognised in the recently published report on the Output, outcomes and impact of MRC research: 2013/14, highlighting research carried out at The Unit that has played a key role in influencing policy.
Today, many partners are concerned with reducing malaria (WHO, National Control Programmes, The Global Fund, etc ) and the current best practice for malaria control is the use of Artemisinin-based combination therapies , e.g. Coartem®, and long-lasting impregnated nets (LLINs) for vector control tool. Many countries are also using indoor residual spraying (IRS) as it […]
Trachoma is the leading infectious cause of blindness worldwide and affects millions of people in poor and rural regions. The Partnership for the Rapid Elimination of Trachoma (PRET) is a cluster randomized control trial taking place in three countries: The Gambia, Tanzania and Niger. It aims to answer two main questions: The WHO recommends that […]
Tuberculosis (TB) is a major health problem especially in the developing world. It has been estimated that one third of the global population is latently infected with Mycobacterium tuberculosis. Despite years of effort we currently have no reliable biomarkers for identifying protective immunity against TB and for the various disease states, or for predicting response […]